ASH 2017 | A novel BTK inhibitor BGB-3111: new data presented at ASH 2017
Constantine Tam
Constantine Tam, MD, from the Peter MacCallum Cancer Centre, Melbourne, Australia tells us about a novel BTK inhibitor, BGB-3111 and how it might compare with existing treatments, such as ibrutinib. Results from three studies on the agent were presented at the ASH 2017 meeting in Atlanta, GA, and Constantine gives us a summary of the data.
Related videos
The current treatment landscape for CLL
John Gribben
The ECOG-E192 and ALLIANCE studies: ibrutinib therapy for CLL
Tait Shanafelt
Anas Younes: two practice-changing abstracts at ASH 2018
Anas Younes
COSMOS: key updates for MOR208 plus venetoclax for R/R CLL
Jennifer Woyach
CLL news from ASH 2018: ibrutinib strikes again!
Stephan Stilgenbauer
